[inhibition of HER3 may be more clinically relevant than inhibition of EGFR in HER2-amplified breast cancer and adding pertuzumab to trastuzumab may augment therapeutic benefit by blocking HER2/HER3 signaling ]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
Gene-disease associations inferred from text-mining the literature.
DisGeNET evidence - LITERATURE